Browse Studies — Arctuva

Phase 2

A Phase 2, Single Arm, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vorasidenib in Pediatric Participants Aged 12 to < 18 Years Old With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric partici…

Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Estimated

~$75 – $3,000

Actual pay is set by the research site.